CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Net product sales	$ 987,909	$ 858,245
Sanofi collaboration revenue	189,490	210,367
Bayer Collaboration Revenue	247,928	193,939
Other revenue	86,158	56,440
Total revenues	1,511,485	1,318,991
Expenses:
Research and development	498,586	507,435
Selling, general, and administrative	330,770	296,846
Cost of goods sold	69,243	61,253
Cost of collaboration and contract manufacturing	45,655	22,915
Total expenses	944,254	888,449
Income from operations	567,231	430,542
Other income (expense):
Other income, net	24,606	9,248
Interest Expense	(6,439)	(7,501)
Total other income (expense)	18,167	1,747
Income before income taxes	585,398	432,289
Income tax expense	(107,418)	(183,358)
Net income	$ 477,980	$ 248,931
Net income per share - basic	$ 4.44	$ 2.36
Net income per share - diluted	$ 4.16	$ 2.16
Weighted average shares outstanding - basic	107,648	105,572
Weighted average shares outstanding - diluted	114,906	115,106
Statements of Comprehensive Income
Net income	$ 477,980	$ 248,931
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on marketable securities	(11,080)	6,956
Unrealized gain on cash flow hedges	1,439	0
Comprehensive income	$ 468,339	$ 255,887